Search Results

Boston Scientific (NYSE: BSX) has announced that it has entered into a definitive agreement to acquire Vertiflex, Inc., a privately-held company which has developed and commercialized the Superion® Indirect Decompression System,

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Vertiflex, Inc., a privately-held company that developed and commercialized the Superion® Indirect Decompression System, a minimally-invasive device used to improve physical function and reduce pain in patients with lumbar spinal stenosis (LSS) – the narrowing of the spinal canal, which can cause compression of nearby nerves.

H.I.G. BioHealth Partners recently announced the sale of Vertiflex, Inc. to Boston Scientific for a total equity value of approximately $465 million in cash and additional payments contingent on the Company attaining certain commercial goals.

Acquisition of lumbar spinal stenosis treatment to expand portfolio of interventional pain therapies

Company milestones demonstrate progress and commercial success of product portfolio

Study published in Journal of Pain Research has important public health implications given current opioid epidemic in the U.S.